-
International Journal of Nephrology and Renovascular Disease
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Prevalence of modifiable cardiovascular risk factors in long-term renal transplant patients
Original Research
(1296) Views (326) Full article downloads
Authors: Vadamalai Vivek, Sunil Bhandari
Published Date December 2010
Volume 2010:3 Pages 175 - 182
DOI: http://dx.doi.org/10.2147/IJNRD.S13866
Vadamalai Vivek1, Sunil Bhandari1,21Department of Renal Medicine, Hull and East Yorkshire Hospitals NHS Trust and Hull York Medical School, East Yorkshire, UK; 2Statewide Renal Services, Department of Renal Medicine, Royal Prince Alfred Hospital, Camperdown, Sydney, Australia
Background: Cardiovascular disease accounts for the majority of morbidity and mortality in renal transplant patients. This relates to a number of modifiable and nonmodifiable risk factors, including new onset diabetes after transplantation (NODAT). We examined the prevalence of these risk factors in a cohort of 126 renal transplant patients.
Methods: A retrospective cross-sectional study of 94 nondiabetic post-transplant (ND) patients (mean age 45.7 ± 13.5 years) and 32 NODAT patients (55.2 ± 9.6 years) was performed. Univariate linear regression analysis was used to identify potential factors that affected cardiovascular events. Multivariable analysis was performed on those factors found to achieve a P value of less than 0.20 after univariate analysis to test for significance in relation to cardiovascular risk as the primary factor.
Results: Mean serum creatinine levels were 131.1 ± 4.3 µmol/L and 135.2 ± 4.9 µmol/L at 96.9 ± 8.7 and 79.4 ± 14.1 months post-transplantation, respectively. Systolic pressure and pulse pressure were significantly higher in NODAT patients (P = 0.016 and P < 0.005). Adequate target blood pressures were obtained in 80% of patients. Low-density lipoprotein and high-density lipoprotein cholesterol were reduced in NODAT (P = 0.04 and P = 0.005). Homocysteine was similarly elevated in both groups (17.5 and 15.6 µmol/L, respectively). Coronary events and/or coronary disease were present in 19.1% of ND and 37.5% of NODAT patients (P < 0.05). Cardiac deaths were three-fold more common (25% versus 7.4%) in patients with NODAT. Univariate analysis revealed diabetes and age, and subsequent multivariable analysis revealed age only, as being significantly associated with cardiovascular outcomes.
Conclusions: Cardiac events are more common in patients with NODAT. Age is an important determinant of cardiovascular risk.
Keywords: blood pressure, cardiovascular risk, diabetes, post-transplant, renal, mortality
Other articles by Professor Sunil Bhandari
Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice
Readers of this article also read:
Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin
Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment
Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?
Cyclosporine A and steroid therapy in childhood steroid-resistant nephrotic syndrome
Update on the diagnosis and management of acute kidney injury
Potential treatment options and future research to increase hepatitis C virus treatment response rate
New and improved strategies for the treatment of gout
Effect of angiotensin II blockade on central blood pressure and arterial stiffness in subjects with hypertension
Mild and moderate pre-dialysis chronic kidney disease is associated with increased coronary artery calcium
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs
- Potential renovascular hypertension, space missions, and the role of magnesium
- The use of everolimus in renal-transplant patients
- Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate




